Get the Stockscreener App
5.83
0.51%
-0.03
After Hours:
5.83
Kezar Life Sciences Inc stock is traded at $5.83, with a volume of 5,558.
It is down -0.51% in the last 24 hours and down -0.68% over the past month.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
See More
Previous Close:
$5.86
Open:
$5.815
24h Volume:
5,558
Relative Volume:
0.16
Market Cap:
$42.54M
Revenue:
-
Net Income/Loss:
$-101.87M
P/E Ratio:
-4.1348
EPS:
-1.41
Net Cash Flow:
$-83.46M
1W Performance:
-4.11%
1M Performance:
-0.68%
6M Performance:
+2.28%
1Y Performance:
-35.93%
1-Day Range:
$5.755
$5.91
1-Week Range:
$5.65
$6.21
52-Week Range:
$5.202
$10.40
Kezar Life Sciences Inc Stock (KZR) Company Profile
Name
Kezar Life Sciences Inc
Sector
Industry
Phone
650-822-5600
Address
4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare KZR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KZR
Kezar Life Sciences Inc
|
5.83 | 42.54M | 0 | -101.87M | -83.46M | -1.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Kezar Life Sciences Inc Stock (KZR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-11-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-16-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Jul-16-18 | Initiated | Jefferies | Buy |
| Jul-16-18 | Initiated | Wells Fargo | Outperform |
| Jul-16-18 | Initiated | William Blair | Outperform |
View All
Kezar Life Sciences Inc Stock (KZR) Latest News
Dermatomyositis Drug Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Treatment Market, Prevalence, Medication, Statistics, Therapies, Companies by DelveInsight - The Globe and Mail
Kezar Life Sciences Inc expected to post a loss of $2.88 a shareEarnings Preview - TradingView
Kezar Life Sciences (KZR) Expected to Announce Quarterly Earnings on Thursday - Defense World
Kezar Life Sciences’ (KZR) Outperform Rating Reiterated at William Blair - Defense World
Kezar stock rating raised to Outperform at William Blair By Investing.com - Investing.com UK
Dermatomyositis Market Generated Opportunities, Future Scope - openPR
(KZR) On The My Stocks Page - Stock Traders Daily
Kezar Life Sciences (KZR) Stock Price, News & Analysis - MarketBeat
Major Clinical Development Update: Stanford Expert Reveals Future of Zetomipzomib in Autoimmune Hepatitis - StockTitan
Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025 - Business Wire
Objective long/short (KZR) Report - Stock Traders Daily
Kezar Life Sciences files for $400M mixed securities shelf - MSN
Autoimmune Hepatitis Market Growth to Accelerate in Forecast - openPR
Kezar Life Sciences Files $400 Million Mixed Securities Shelf -February 05, 2025 at 05:55 pm EST - Marketscreener.com
Kezar Life Sciences, Inc. (NASDAQ:KZR) Short Interest Update - Defense World
Kezar reports preliminary year-end financial position - Investing.com
Wells Fargo & Company Issues Pessimistic Forecast for Kezar Life Sciences (NASDAQ:KZR) Stock Price - Defense World
HC Wainwright Issues Pessimistic Estimate for KZR Earnings - Defense World
Q4 EPS Estimate for Kezar Life Sciences Decreased by Analyst - MarketBeat
Kezar Life Sciences updates shareholder rights agreement - Investing.com
Kezar Life Sciences (NASDAQ:KZR) Given “Neutral” Rating at HC Wainwright - Defense World
William Blair Has Strong Estimate for KZR FY2024 Earnings - MarketBeat
FY2024 Earnings Estimate for KZR Issued By William Blair - Defense World
Kezar Life Sciences (NASDAQ:KZR) and Summit Therapeutics (NASDAQ:SMMT) Head-To-Head Contrast - Defense World
Wells Fargo & Company Has Lowered Expectations for Kezar Life Sciences (NASDAQ:KZR) Stock Price - Defense World
Kezar struck again with second FDA hold - Clinical Trials Arena
Kezar Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Kezar Life Sciences (NASDAQ:KZR) Receives "Market Perform" Rating from William Blair - MarketBeat
Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update - Business Wire
Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR) - Business Wire
Kezar Life Sciences stock hits 52-week high at $7.5 By Investing.com - Investing.com South Africa
Kezar Life Sciences (NASDAQ:KZR) Shares Gap DownHere's What Happened - MarketBeat
Kezar Life Sciences announces 1-for-10 reverse stock split - MSN
Kezar Life Sciences stock hits 52-week high at $7.5 - Investing.com
Kezar Life Sciences announces 1-for-10 reverse stock split By Investing.com - Investing.com Canada
Kezar Life Sciences Stock Scheduled to Reverse Split on Wednesday, October 30th (NASDAQ:KZR) - MarketBeat
Kezar Life Sciences to Implement 1-for-10 Reverse Stock Split - Marketscreener.com
Kezar Life Sciences Announces 1-for-10 Reverse Stock Split - BioSpace
Kezar Life Sciences Announces 1-for-10 Reverse Stock Split | KZR Stock News - StockTitan
What Makes Kezar Life Sciences (KZR) a New Buy Stock - MSN
Kezar shares unchanged as takeover bid rejected By Investing.com - Investing.com UK
Kezar Life Sciences discontinues lupus nephritis programme after fatalities - Clinical Trials Arena
Kezar rejects Concentra's acquisition offer, adopts rights plan By Investing.com - Investing.com South Africa
Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update - BioSpace
Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study - Benzinga
Concentra Biosciences, LLC cancelled the acquisition of Kezar Life Sciences, Inc. from Tang Capital Partners, LP, managed by Tang Capital Management, LLC and others. - Marketscreener.com
Kezar stock falls 11% after board rejects Concentra offer (NASDAQ:KZR) - Seeking Alpha
Kezar discontinues development of zetomipzomib for lupus nephritis (NASDAQ:KZR) - Seeking Alpha
Kezar stock falls 11% after board rejects Concentra offer (update) - MSN
Kezar to discontinue mid-stage trial for lupus treatment - Reuters
Kezar rejects Concentra's acquisition offer, adopts rights plan - Investing.com
Kezar Life Sciences Inc Stock (KZR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):